What is Shandong Weigao Group Medical Polymer Co ROA %?
Shandong Weigao Group Medical Polymer CoSHWGY -5.57%70 ROA % is 3.38% as of Dec. 2025, which is 54% below its 10-year median of 7.30. GuruFocus rates SHWGY with a GF Score™ of 70/100 and a GF Value™ of $2.98 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Shandong Weigao Group Medical Polymer Co ranks better than 68.26% on this metric.
SHWGY's ROA % is ranked better than 68.26% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.56
vs SHWGY: 4.56
Shandong Weigao Group Medical Polymer Co (OTCPK:SHWGY) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Shandong Weigao Group Medical Polymer Co ROA % Related Terms
Shandong Weigao Group Medical Polymer Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co ROA % Chart
Shandong Weigao Group Medical Polymer Co Annual Data
For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Group Medical Polymer Co ROA % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Shandong Weigao Group Medical Polymer Co (SHWGY) has a ROA % of 3.38% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. This is 54% below median its historical median of 7.30. Over the past decade, Shandong Weigao Group Medical Polymer Co's ROA % has ranged from 4.56 to 10.91. According to the industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #272 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 31.7%.
Is Shandong Weigao Group Medical Polymer Co's ROA % too high?
Shandong Weigao Group Medical Polymer Co's current ROA % of 3.38% is 54% below median its 10-year median of 7.30. Over the past 10 years, this metric has ranged from a low of 4.56 to a high of 10.91. The Medical Devices & Instruments industry median ROA % is 0.56. Shandong Weigao Group Medical Polymer Co's value of 3.38% is 503.6% above this industry median. Based on the distribution chart, Shandong Weigao Group Medical Polymer Co ranks #272 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Group Medical Polymer Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Group Medical Polymer Co's ROA % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #272 out of 857 companies for ROA %. This puts Shandong Weigao Group Medical Polymer Co in the upper half of its industry. The industry median ROA % is 0.56. Shandong Weigao Group Medical Polymer Co's value of 3.38% is 503.6% above this benchmark. Historically, Shandong Weigao Group Medical Polymer Co's own ROA % has ranged from 4.56 to 10.91 over the past decade. While the company's 10-year median is 7.30 vs. the industry median of 0.56, Shandong Weigao Group Medical Polymer Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.56, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Group Medical Polymer Co's current ROA % of 3.38% is 503.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Group Medical Polymer Co's current ROA % is 3.38%, which is 54% below median its own 10-year median of 7.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Group Medical Polymer Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co (SHWGY) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.98, compared to a current price of $1.49 — trading 49.9% below its estimated fair value. The current ROA % is 3.38%, which is 54% below median its 10-year median of 7.30 and 503.6% above the Medical Devices & Instruments industry median of 0.56. Shandong Weigao Group Medical Polymer Co's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Shandong Weigao Group Medical Polymer Co (SHWGY), the current ROA % is 3.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Weigao Group Medical Polymer Co (SHWGY) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co stock appears to be undervalued.
The current stock price of $1.49 is trading 49.9% below its estimated GF Value™ of $2.98.
GuruFocus considers Shandong Weigao Group Medical Polymer Co to be Significantly Undervalued.
Key valuation signals for SHWGY:
ROA %: 3.38% (54% below median its 10-year median of 7.30)
GF Value™: $2.98 vs. price of $1.49 (49.9% below fair value)
Industry Position: 503.6% above the Medical Devices & Instruments median (#272 of 857)
No single metric tells the full story. See the SHWGY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Weigao Group Medical Polymer Co Business Description
Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.
70GF Score
Get the complete analysis for SHWGY
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHWGY has been successfully added to your 
